CLLS
HealthcareCellectis S.A.
$4.54
$-0.26 (-5.42%)
Jan 5, 2026
Price History (1Y)
Analysis
Cellectis S.A. is a biotechnology company listed in the healthcare sector with a market capitalization of $455.48M and revenue of $82.55M (TTM). The company has a relatively small workforce of 216 employees. The company's financial health indicates significant net losses, with a Net Income (TTM) of -$35,353,000, and negative returns on equity (-30.8%) and assets (-4.5%). However, the gross margin is at 100.0%, indicating that costs are being managed effectively. The balance sheet shows $88.85M in debt against $52.24M in cash, resulting in a debt to equity ratio of 88.43. The valuation context for Cellectis S.A. is characterized by a negative forward P/E of -7.32 and an EV/EBITDA of -27.66. The revenue growth rate is 105.9% (YoY), but the earnings growth rate is not available due to net losses. Dividend information is not applicable, as there is no dividend yield or payout ratio reported.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Visit website →Key Statistics
- Market Cap
- $455.48M
- P/E Ratio
- N/A
- 52-Week High
- $5.48
- 52-Week Low
- $1.10
- Avg Volume
- 141.17K
- Beta
- 2.98
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- France
- Employees
- 216